Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-β1

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Fan, Xiaobao ^a   Zhang, Qiannan ^a   Li, Shuang ^a   Lv, Yifei ^a   Su, Houqiang ^a   Jiang, Huiping ^a   Hao, Zhiming ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 2; KEYHOLE LIMPET HEMOCYANIN; PEPTIDE VACCINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD2 PROTEIN; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1 25 [41-65] KINOID VACCINE; TRANSFORMING GROWTH FACTOR BETA1 30 [83-112] KINOID VACCINE; TRANSFORMING GROWTH FACTOR BETA1 KINOID VACCINE; UNCLASSIFIED DRUG; ANTISERUM; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; SMAD PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; ATTENUATION; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CELL PROLIFERATION; CONTROLLED STUDY; CROSS LINKING; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STELLATE CELL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; HUMAN; IMMUNOLOGY; LIVER; LIVER CELL; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; RAT; VACCINATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; APOPTOSIS; CARBON TETRACHLORIDE; CELL PROLIFERATION; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED BALB C; RATS; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; VACCINATION;

EID: 84892391287     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082190     Document Type: Article

References (40)

1. Friedman SL (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247-2250. doi:10.1074/jbc.275.4.2247. PubMed: 10644669.
2. Thompson AJ, Patel K (2010) Antifibrotic therapies: will we ever get there? Curr Gastroenterol Rep 12: 23-29. doi:10.1007/s11894-009-0080-9. PubMed: 20425481.
3. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP et al. (1999) TGF-β1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 276: G1059-G1068. PubMed: 10198351.
4. Russell WE, Coffey RJ Jr., Ouellette AJ, Moses HL (1988) Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci U S A 85: 5126-5130. doi:10.1073/pnas.85.14.5126. PubMed: 3164865.
5. Oberhammer F, Bursch W, Tiefenbacher R, Fröschl G, Pavelka M et al. (1993) Apoptosis is induced by transforming growth factor-β1 within 5 hours in regressing liver without significant fragmentation of the DNA. Hepatology 18: 1238-1246. doi:10.1002/hep.1840180533. PubMed: 8225231.
6. Cheng K, Yang N, Mahato RI (2009) TGF-β1 gene silencing for treating liver fibrosis. Mol Pharm 6: 772-779. doi:10.1021/mp9000469. PubMed: 19388665.
7. Okuno M, Akita K, Moriwaki H, Kawada N, Ikeda K et al. (2001) Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 120: 1784-1800. doi:10.1053/gast.2001.24832. PubMed: 11375959.
8. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E (1990) Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 346: 371-374. doi:10.1038/346371a0. PubMed: 2374609.
9. Ling H, Roux E, Hempel D, Tao J, Smith M et al. (2013) Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLOS ONE; 8(1): e54499. doi:10.1371/journal.pone.0054499. PubMed: 23349909.
10. Ueno H, Sakamoto T, Nakamura T, Qi Z, Astuchi N et al. (2000) A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. Hum Gene Ther 11: 33-42. doi:10.1089/10430340050016139. PubMed: 10646637.
11. George J, Roulot D, Koteliansky VE, Bissell DM (1999) In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor: A potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 96: 12719-12724. doi:10.1073/pnas.96.22.12719. PubMed: 10535989.
12. Yata Y, Gotwals P, Koteliansky V, Rockey DC (2002) Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-β soluble receptor: implications for antifibrotic therapy. Hepatology 35: 1022-1030. doi:10.1053/jhep.2002.32673. PubMed: 11981752.
13. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H (1999) Blockade of type β transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci U S A 96: 2345-2349. doi:10.1073/pnas.96.5.2345. PubMed: 10051644.
14. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H (2000) Inhibition of transforming growth factor β prevents progression of liver fibrosis and enhances hepatocyte regeneration in Dimethylnitrosamine - treated rats. Hepatology 32: 247-255. doi:10.1053/jhep.2000.9109. PubMed: 10915731.
15. San-Martin A, Dotor J, Martinez F, Hontanilla B (2010) Effect of the inhibitor peptide of the transforming growth factor beta (p144) in a new silicone pericapsular fibrotic model in pigs. Anesthetic Plast Surg 34: 430-437. doi:10.1007/s00266-010-9475-0.
16. Kinoshita K, Iimuro Y, Otogawa K, Saika S, Inagaki Y et al. (2007) Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut 56: 706-714. doi:10.1136/gut.2006.092460. PubMed: 17127702.
17. Zagury D, Burny A, Gallo RC (2001) Toward a new generation of vaccines: The anti-cytokine therapeutic vaccines. Proc Natl Acad Sci U S A 98: 8024-8029. doi:10.1073/pnas.141224798. PubMed: 11438746.
18. Zagury D, Le Buanec H, Bizzini B, Burny A, Lewis G et al. (2003) Active versus passive anticytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev 14: 123-137. doi:10.1016/S1359-6101(03) 00004-2. PubMed: 12651224.
19. González G, Crombet T, Catalá M, Catala M, Alfonso L et al. (1998) A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 9: 431-435. doi:10.1023/A:1008261031034. PubMed: 9636835.
20. Zagury D, Lecoq H, Gervi L, Le Buanec H, Zagury JF et al. (1999) Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum - an adjuvant to antiretroviral tritherapy. Biomed Pharmacother 53: 90-92. doi:10.1016/S0753-3322(99)80065-1. PubMed: 10337463.
21. Dalum I, Butler DM, Jensen MR, Hindersson P, Steinaa L et al. (1999) Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 17: 666-669. doi:10.1038/10878. PubMed: 10404159.
22. Gonzalez G, Crombet T, Torres F, Mirabal V, Hernández JC et al. (2003) Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 14: 461-466. doi:10.1093/annonc/mdg102. PubMed: 12598354.
23. Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmäki N et al. (2006) A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A 103: 9208-9213. doi:10.1073/pnas. 0603110103. PubMed: 16754857.
24. Le Buanec H, Delavallée L, Bessis N, Paturance S, Bizzini B et al. (2006) TNFα kinoid vaccination-induced neutralizing antibodies to TNFα protect mice from autologous TNFα-driven chronic and acute inflammation. Proc Natl Acad Sci U S A 103: 19442-19447. doi:10.1073/pnas. 0604827103. PubMed: 17158801.
25. González G, Crombet T, Neninger E, Viada C, Lage A (2007) Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: Analysis of pooled data from three clinical trials. Hum Vaccin 3: 8-13. doi:10.4161/hv.3.1.3537. PubMed: 17204867.
26. Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P et al. (2007) VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A 104: 2837-2842. doi:10.1073/pnas. 0611022104. PubMed: 17301234.
27. Vinageras EN, de la Torre A, Osorio Rodríguez M, Catalá Ferrer M, Bravo I et al. (2008) Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26: 1452-1458. doi:10.1200/JCO.2007.11.5980. PubMed: 18349395.
28. Delavallée L, Le Buanec H, Bessis N, Assier E, Denys A et al. (2008) Early and long-lasting protection from arthritis in tumour necrosis factor α (TNFα) transgenic mice vaccinated against TNFα. Ann Rheum Dis 67: 1332-1338. PubMed: 18042641.
29. Spohn G, Keller I, Beck M, Grest P, Jennings GT et al. (2008) Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol 38: 877-887. doi:10.1002/eji.200737989. PubMed: 18253928.
30. Tohyama S, Onodera S, Tohyama H, Yasuda K, Nishihira J et al. (2008) A novel DNA vaccine-targeting macrophage migration inhibitory factor improves the survival of mice with sepsis. Gene Ther 15: 1513-1522. doi:10.1038/gt.2008.112. PubMed: 18650852.
31. Dalum I, Jensen MR, Hindersson P, Elsner H, Mouritsen S (1996) Breaking B cell tolerance toward a highly conserved self protein. J Immunol 157: 4796-4808. PubMed: 8943381.
32. Qian SW, Burmester JK, Tsang ML, Weatherbee JA, Hinck AP et al. (1996) Binding affinity of transforming growth factor-beta for its type II receptor is determined by the C-terminal region of the molecule. J Biol Chem 271: 30656-30662. doi:10.1074/jbc.271.48.30656. PubMed: 8940041.
33. Huang SS, Zhou M, Johnson FE, Shieh HS, Huang JS (1999) An active site of transforming growth factor-beta 1 for growth inhibition and stimulation. J Biol Chem 274: 27754-27758. doi:10.1074/jbc.274.39.27754. PubMed: 10488119.
34. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699. doi:10.1016/0168-8278(95)80226-6. PubMed: 7560864.
35. Reddy GK, Enwemeka CS (1996) A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 29: 225-229. doi:10.1016/0009-9120(96)00003-6. PubMed: 8740508.
36. Ballardini G, Fallani M, Biagini G, Bianchi FB, Pisi E (1988) Desmin and actin in the identification of Ito cells and in monitoring their evolution to myofibroblasts in experimental liver fibrosis. Virchows Arch B Cell Pathol Incl Mol Pathol 56: 45-49. doi:10.1007/BF02890000. PubMed: 2907200.
37. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T (2002) Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 36: 200-209. doi:10.1016/S0168-8278(01)00260-4. PubMed: 11830331.
38. 4-induced hepatic fibrosis in mice. J Pharmacol Exp Ther 342: 835-842. doi:10.1124/jpet.112.194357. PubMed: 22711911.
39. Giri SN, Hyde DM, Hollinger MA (1993) Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 48: 959-966. doi:10.1136/thx.48.10.959. PubMed: 7504843.
40. Cheong HJ, Song JY, Park JW, Yeon JE, Byun KS et al. (2006) Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosis. Vaccine 24: 2417-2422. doi:10.1016/j.vaccine.2005.11.064. PubMed: 16406176.